Drug: Calciferol

ERGOCALCIFEROL (ergocalciferol) CAPSULES, USP, is a synthetic calcium regulator for oral administration. Ergocalciferol (ergocalciferol) is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. It is affected by air and by light. Ergosterol or provitamin D2 is found in plants and yeast and has no antirachitic activity. There are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin D or antirachitic activity. One USP Unit of vitamin D2 is equivalent to one International Unit (IU), and 1 mcg of vitamin D2 is equal to 40 IU. Each softgel, for oral administration, contains Ergocalciferol (ergocalciferol) , USP 1.25 mg (equivalent to 50,000 USP units of Vitamin D), in an edible vegetable oil. Ergocalciferol (ergocalciferol) , also called vitamin D2, is 9, 10-secoergosta-5,7,10(19),22-tetraen-3-ol,(3 ≤ ,5Z,7E,22E)-; (C28H44O) with a molecular weight of 396.65, and has the following structural formula: Inactive Ingredients: Refined soybean oil, gelatin, glycerin, purified water, D&C Yellow #10, and FD&C Blue #1.

Source: http://www.rxlist.com

Hypervitaminosis D is characterized by effects on the following organ system: Renal Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS Mental retardation. Soft Tissues Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Skeletal Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism), vague aches, stiffness, and weakness. Gastrointestinal Nausea, anorexia, constipation. Metabolic Mild acidosis, anemia, weight loss. Read the Calciferol (ergocalciferol) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets 12,000 to 500,000 USP units daily. Hypoparathyroidism 50,000 to 200,000 USP units daily concomitantly with calcium lactate 4 g, six times per day. DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorous determinations must be made every 2 weeks or more frequently if necessary. X-rays of the bones should be taken every month until condition is corrected and stabilized.

Source: http://www.rxlist.com

Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol (ergocalciferol) may cause hypercalcemia. Read the Calciferol Drug Interactions Center for a complete guide to possible interactions Learn More »

Source: http://www.rxlist.com

Ergocalciferol (ergocalciferol) is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

Source: http://www.rxlist.com

Ergocalciferol (ergocalciferol) is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D. Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

The effects of administered vitamin D can persist for two or more months after cessation of treatment. Hypervitaminosis D is characterized by:
  • Hypercalcemia with anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, mental retardation, anemia, and mild acidosis.
  • Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, or irreversible renal insufficiency which may result in death.
  • Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Bone demineralization (osteoporosis) in adults occurs concomitantly.
  • Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism).
The treatment of hypervitaminosis D with hypercalcemia consists in immediate withdrawal of the vitamin, a low calcium diet, generous intake of fluids, along with symptomatic and supportive treatment. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diuretic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acid), and mithramycin via appropriate regimens. With appropriate therapy, recovery is the usual outcome when no permanent damage has occurred. Deaths via renal or cardiovascular failure have been reported. The LD50 in animals is unknown. The toxic oral dose of ergocalciferol (ergocalciferol) in the dog is 4 mg/kg.

Source: http://www.rxlist.com

Each green, oval softgel is imprinted with PA140 and contains 1.25 mg (50,000 USP units vitamin D) of ergocalciferol (ergocalciferol) , USP, and is available in bottles of 100 or 1000 Softgels. Store at controlled room temperature 15°-30°C (59°-86°F). Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP. Manufactured by : Banner Pharmacaps, Inc., 4125 Premier Drive, High Point, NC 27265. FDA revision date: n/a Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General Vitamin D administration from fortified foods, dietary supplements, self-administered and prescription drug sources should be evaluated. Therapeutic dosage should be readjusted as soon as there is clinical improvement. Dosage levels must be individualized and great care exercised to prevent serious toxic effects. IN VITAMIN D RESISTANT RICKETS THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. When high therapeutic doses are used progress should be followed with frequent blood calcium determinations. In the treatment of hypoparathyroidism, intravenous calcium, parathyroid hormone, and/or dihy-drotachysterol may be required. Maintenance of a normal serum phosphorous level by dietary phosphate restriction and/or administration of aluminum gels as intestinal phosphate binders in those patients with hyperphosphatemia as frequently seen in renal osteodystrophy is essential to prevent metastatis calcification. Adequate dietary calcium is necessary for clinical response to vitamin D therapy. Protect from light. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the drug's potential in these areas. Pregnancy Pregnancy Category C Animal reproduction studies have shown fetal abnormalities in several species associated with hypervitaminosis D. These are similar to the supravalvular aortic stenosis syndrome described in infants by Black in England (1963). This syndrome was characterized by supravalvular aortic stenosis, elfin facies, and mental retardation. For the protection of the fetus, therefore, the use of vitamin D in excess of the recommended dietary allowance during normal pregnancy should be avoided unless, in the judgment of the physician, potential benefits in a specific, unique case outweigh the significant hazards involved. The safety in excess of 400 USP units of vitamin D daily during pregnancy has not been established. Nursing Mothers Caution should be exercised when ergocalciferol (ergocalciferol) is administered to a nursing woman. In a mother given large doses of vitamin D, 25-hydroxycholecalciferol (ergocalciferol) appeared in the milk and caused hypercalcemia in her child. Monitoring of the infants serum calcium concentration is required in that case (Goldberg, 1972). Pediatric Use Pediatric doses must be individualized (see DOSAGE AND ADMINISTRATION). Last reviewed on RxList: 12/29/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Women's Health Care an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Calciferol. Find what medications you are taking today.